Holen Sie sich die Stockscreener-App
5.99
2.92%
-0.18
Handel nachbörslich:
5.73
-0.26
-4.34%
Schlusskurs vom Vortag:
$6.17
Offen:
$6.05
24-Stunden-Volumen:
803.29K
Relative Volume:
0.42
Marktkapitalisierung:
$24.37M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-54.66M
KGV:
-0.3141
EPS:
-19.0729
Netto-Cashflow:
$-49.98M
1W Leistung:
+204.06%
1M Leistung:
+172.27%
6M Leistung:
-53.60%
1J Leistung:
+16.76%
1-Tages-Spanne:
$5.6801
$6.50
1-Wochen-Bereich:
$1.70
$9.90
52-Wochen-Spanne:
$1.55
$15.74
Nextcure Inc Stock (NXTC) Company Profile
Firmenname
Nextcure Inc
Sektor
Branche
Telefon
240-399-4900
Adresse
9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE, MD
Compare NXTC vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NXTC
Nextcure Inc
|
5.99 | 25.11M | 0 | -54.66M | -49.98M | -19.07 |
VRTX
Vertex Pharmaceuticals Inc
|
485.65 | 123.36B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.69 | 71.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
860.55 | 53.68B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
186.16 | 38.09B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
267.47 | 37.80B | 4.29B | 577.22M | 641.34M | 4.2086 |
Nextcure Inc Stock (NXTC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-07 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2022-11-04 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2022-03-01 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2021-03-05 | Hochstufung | Truist | Hold → Buy |
| 2021-01-15 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-07-16 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2020-07-13 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2020-07-13 | Herabstufung | SunTrust | Buy → Hold |
| 2020-06-01 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2020-06-01 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2020-05-26 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-03-24 | Eingeleitet | The Benchmark Company | Buy |
| 2020-03-02 | Eingeleitet | ROTH Capital | Buy |
| 2020-01-13 | Eingeleitet | SunTrust | Buy |
| 2019-12-05 | Eingeleitet | Needham | Buy |
| 2019-11-26 | Eingeleitet | BTIG Research | Buy |
| 2019-07-09 | Eingeleitet | BofA/Merrill | Buy |
| 2019-06-03 | Eingeleitet | Morgan Stanley | Overweight |
| 2019-06-03 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Nextcure Inc Aktie (NXTC) Neueste Nachrichten
NextCure Inc. (NXTC) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
NextCure and Avere Therapeutics Announce Merger and $320 Million Private Financing - Global Legal Chronicle
NextCure (NASDAQ: NXTC) details Avere merger structure and S-4 plan - Stock Titan
NextCure (NXTC) Slides As Avere Merger Triggers Legal Scrutiny - StocksToTrade
H.C. Wainwright reiterates NextCure stock rating on merger news - Investing.com
H.C. Wainwright reiterates NextCure stock rating on merger news By Investing.com - Investing.com UK
Beltsville's NextCure merging with San Francisco startup - The Business Journals
Dow Falls Over 100 Points Following Inflation Data; Crude Oil Gains - Sahm
NextCure Announces Transformative All-Stock Merger With Avere - TipRanks
NextCure, Avere Therapeutics enter definitive merger agreement - TipRanks
Law firm investigates if NextCure shareholders get a fair price in merger with Avere Therapeutics. - Pluang
NXTC Stock Alert: Halper Sadeh LLC is Investigating Whether NextCure, Inc. is Obtaining a Fair Price for its Shareholders - GlobeNewswire Inc.
Avere, NextCure Merge To Take AVR-001 Ahead In Psoriasis, Ulcerative Colitis - insights.citeline.com
After $5 billion-plus Novo Nordisk buyout, this biotech band is playing an encore with big merger plans - The Business Journals
Power Moves: NXTC, TOON, SHPH, COCH Entry Points Ignite on Major Catalysts - FinancialContent
Why Did NextCure Stock 3X In One Session?NextCure (NASDAQ:NXTC) - Benzinga
Law firm investigates NextCure merger fairness as shareholders get 1.21% stake in combined company - Pluang
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of NextCure, Inc. (NASDAQ: NXTC) - PR Newswire
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
NextCure, Inc. (NXTC) Stock: Soars 218% After Avere Merger and $320M Private Placement Deal - parameter.io
NextCure stock surge puts cash payout and 1.21% Avere stake under the lens - TechStock²
NextCure faces investigation over merger terms with Avere Therapeutics amid shareholder concerns. - Pluang
NextCure and Avere Therapeutics Announce $320M Merger to Advance Once-Weekly Oral IL-23 Therapy for Psoriasis and Ulcerative Colitis 12 – Minichart - Minichart
Shareholder Alert: Ademi LLP investigates whether NextCure, Inc. is obtaining a Fair Price for Public Shareholders - PR Newswire
NXTC Stock Alert: Halper Sadeh LLC is Investigating Whether NextCure, Inc. is Obtaining a Fair Price for its Shareholders - Business Wire
NextCure skyrockets on Avere reverse-merger deal and $320 million financing plan - Quiver Quantitative
NextCure backs Avere merger with $320 million financing - grafa.com
Avery Therapeutics, Inc. entered into a definitive merger agreement to acquire NextCure, Inc. for $250 million in a reverse merger transaction. - marketscreener.com
NXTC Stock Rockets On Massive Volume As Traders Pile In - StocksToTrade
NextCure to merge with Avere Therapeutics in $320M deal By Investing.com - Investing.com Australia
NextCure (NXTC) Stock Skyrockets 300% Following $320M Avere Therapeutics Merger Agreement - parameter.io
NextCure (NXTC) Stock Rockets 300% Following $320M Avere Therapeutics Merger Announcement - MoneyCheck
NextCure (NXTC) Stock Skyrockets 300% Following $320 Million Avere Therapeutics Merger Agreement - Blockonomi
NextCure (NXTC) Stock Surges 300% on $320M Merger Deal With Avere Therapeutics - CoinCentral
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
NextCure and Avere Therapeutics Merge, Raise $320 Million to Advance Oral IL-23 Program - citybiz
Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pill - Yahoo Finance
NextCure to merge with privately-held Avere (NXTC:NASDAQ) - Seeking Alpha
NextCure (NASDAQ: NXTC) plans reverse merger; Avere holders to own about 98% - Stock Titan
NextCure to Merge With Avere in Stock Deal; $320 Million PIPE to Fund Combined Company - TradingView
NextCure (NASDAQ: NXTC) sets Avere merger backed by $320M raise - Stock Titan
NextCure to merge with Avere Therapeutics in $320M deal - Investing.com
NextCure and Avere Therapeutics Announce Definitive Merger and $320 Million Financing to Advance Oral IL-23 Therapy AVR-001 - Quiver Quantitative
NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy - The Manila Times
After $4.7B sale to Novo Nordisk, former Akero team announces new I&I company with China drug - Endpoints News
What's going on with NextCure stock Wednesday? - MSN
Price to sales forward of NextCure, Inc. – NASDAQ:NXTC - TradingView
Price to sales forward of NextCure, Inc. – LSX:A41AKJ - TradingView
Enterprise value to EBITDA forward of NextCure, Inc. – NASDAQ:NXTC - TradingView
Enterprise value to EBITDA forward of NextCure, Inc. – MUN:2US0 - TradingView
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Finanzdaten der Nextcure Inc-Aktie (NXTC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.80%
2.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):